Clinical Trial Update: Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating double versus standard doses of empapagliflozin for metabolic syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• Empapagliflozin (empapagliflozin)

Snippet

Sponsor: Collegium Medicum w Bydgoszczy | Conditions: Metabolic Syndrome | Phase 3 | Status: RECRUITING